Advances in gene therapy for muscular dystrophies.

F1000Research

Volumn 5, Issue , 2016, Pages

  Abdul Razak, Hayder ^a   Malerba, Alberto ^a   Dickson, George ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRISAPERSEN; ETEPLIRSEN;

CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; DMD GENE; DNA END JOINING REPAIR; DUCHENNE MUSCULAR DYSTROPHY; GENE; GENE EDITING; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RNA PROCESSING; TRANS SPLICING;

EID: 85011008868     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.8735.1     Document Type: Review

References (70)

1. Mah JK, Korngut L, Dykeman J, et al.: A systematic review and metaanalysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014; 24(6): 482-91
2. Judge LM, Haraguchiln M, Chamberlain JS: Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. J Cell Sci. 2006; 119(Pt 8): 1537-46
3. Ramos J, Chamberlain JS: Gene Therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs. 2015; 3(11): 1255-66
4. Konieczny P, Swiderski K, Chamberlain JS: Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve. 2013; 47(5): 649-63
5. Jarmin S, Kymalainen H, Popplewell L, et al.: New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Expert Opin Biol Ther. 2014; 14(2): 209-30
6. Fairclough RJ, Wood MJ, Davies KE: Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013; 14(6): 373-8
7. Long C, McAnally JR, Shelton JM, et al.: Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science. 2014; 345(6201): 1184-8
8. Emery AEH, Muntoni F: Duchenne Muscular Dystrophy. OUP Oxford, 2003
9. Cox GF, Kunkel LM: Dystrophies and heart disease. Curr Opin Cardiol. 1997; 12(3): 329-43
10. Zhu X, Wheeler MT, Hadhazy M, et al.: Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. FASEB J. 2002; 16(9): 1096-8
11. Townsend D, Yasuda S, Li S, et al.: Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther. 2008; 16(5): 832-5
12. Martone J, Briganti F, Legnini I, et al.: The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype. Nat Commun. 2016; 7: 10488
13. Aartsma-Rus A, Fokkema I, Verschuuren J, et al.: Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009; 30(3): 293-9
14. Fairclough RJ, Perkins KJ, Davies KE: Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy. Curr Gene Ther. 2012; 12(3): 206-44
15. Emery A: Muscular dystrophy-the facts. Neuromuscul Disord. 1995; 5(6): 521
16. Bladen CL, Salgado D, Monges S, et al.: The TREAT-NMD DMD Global Database: analysis of more than 7, 000 Duchenne muscular dystrophy mutations. Hum Mutat. 2015; 36(4): 395-402
17. Neri M, Torelli S, Brown S, et al.: Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord. 2007; 17(11-12): 913-8
18. Cavazzana-Calvo M, Fischer A: Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest. 2007; 117(6): 1456-65
19. Athanasopoulos T, Graham IR, Foster H, et al.: Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther. 2004; 11(Suppl 1): S109-21
20. Blankinship MJ, Gregorevic P, Chamberlain JS: Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther. 2006; 13(2): 241-9
21. Fang H, Lai NC, Gao MH, et al.: Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer. Hum Gene Ther Methods. 2012; 23(4): 234-41
22. Koo T, Malerba A, Athanasopoulos T, et al.: Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of a1-syntrophin and a-dystrobrevin in skeletal muscles of mdx mice. Hum Gene Ther. 2011; 22(11): 1379-88
23. Hayashita-Kinoh H, Yugeta N, Okada H, et al.: Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance. Mol Ther. 2015; 23(4): 627-37
24. Wang Z, Storb R, Halbert CL, et al.: Successful regional delivery and longterm expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther. 2012; 20(8): 1501-7
25. Bostick B, Shin JH, Yue Y, et al.: AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy. J Mol Cell Cardiol. 2012; 53(2): 217-22
26. Mendell JR, Campbell K, Rodino-Klapac L, et al.: Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med. 2010; 363(15): 1429-37
27. Mays LE, Wilson JM: The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther. 2011; 19(1): 16-27
28. Yan Z, Zhang Y, Duan D, et al.: Trans-splicing vectors expand the utility of adenoassociated virus for gene therapy. Proc Natl Acad Sci U S A. 2000; 97(12): 6716-21
29. Sun L, Li J, Xiao X: Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med. 2000; 6(5): 599-602
30. Nakai H, Storm TA, Kay MA: Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol. 2000; 18(5): 527-32
31. Lai Y, Yue Y, Liu M, et al.: Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol. 2005; 23(11): 1435-9
32. Ghosh A, Yue Y, Long C, et al.: Efficient whole-body transduction with transsplicing adeno-associated viral vectors. Mol Ther. 2007; 15(4): 750-5
33. Duan D, Yue Y, Engelhardt JF: Expanding AAV packaging capacity with transsplicing or overlapping vectors: a quantitative comparison. Mol Ther. 2001; 4(4): 383-91
34. Yue Y, Liu M, Duan D: C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. Mol Ther. 2006; 14(1): 79-87
35. Li J, Sun W, Wang B, et al.: Protein trans-splicing as a means for viral vectormediated in vivo gene therapy. Hum Gene Ther. 2008; 19(9): 958-64
36. Koo T, Popplewell L, Athanasopoulos T, et al.: Triple trans-splicing adenoassociated virus vectors capable of transferring the coding sequence for fulllength dystrophin protein into dystrophic mice. Hum Gene Ther. 2014; 25(2): 98-108
37. Gellhaus K, Cornu TI, Heilbronn R, et al.: Fate of recombinant adeno-associated viral vector genomes during DNA double-strand break-induced gene targeting in human cells. Hum Gene Ther. 2010; 21(5): 543-53
38. Pruett-Miller SM, Connelly JP, Maeder ML, et al.: Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. Mol Ther. 2008; 16(4): 707-17
39. Chapdelaine P, Pichavant C, Rousseau J, et al.: Meganucleases can restore the reading frame of a mutated dystrophin. Gene Ther. 2010; 17(7): 846-58
40. Rousseau J, Chapdelaine P, Boisvert S, et al.: Endonucleases: tools to correct the dystrophin gene. J Gene Med. 2011; 13(10): 522-37
41. Benabdallah BF, Duval A, Rousseau J, et al.: Targeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation. Mol Ther Nucleic Acids. 2013; 2(1): e68
42. Ousterout DG, Perez-Pinera P, Thakore PI, et al.: Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther. 2013; 21(9): 1718-26
43. Ousterout DG, Kabadi AM, Thakore PI, et al.: Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol Ther. 2015; 23(3): 523-32
44. Popplewell L, Koo T, Leclerc X, et al.: Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in. Hum Gene Ther. 2013; 24(7): 692-701
45. Nelson CE, Hakim CH, Ousterout DG, et al.: In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science. 2016; 351(6271): 403-7
46. Li HL, Fujimoto N, Sasakawa N, et al.: Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports. 2015; 4(1): 143-54
47. Maggio I, Stefanucci L, Janssen JM, et al.: Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations. Nucleic Acids Res. 2016; 44(3): 1449-70
48. Bertoni C: Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells. Front Physiol. 2014; 5: 148
49. Popplewell LJ, Malerba A, Dickson G: Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers. Methods Mol Biol. 2012; 867: 143-67
50. Betts CA, Hammond SM, Yin HF, et al.: Optimizing tissue-specific antisense oligonucleotide-peptide conjugates. Methods Mol Biol. 2012; 867: 415-35
51. Muntoni F, Wood MJ: Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov. 2011; 10(8): 621-37
52. Dunckley MG, Eperon IC, Dickson G: Modulation of pre-mRNA splicing in the Duchenne muscular dystrophy gene. Biochem Soc Trans. 1996; 24(2): 276S
53. Han G, Gu B, Cao L, et al.: Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice. Nat Commun. 2016; 7: 10981
54. Long C, Amoasii L, Mireault AA, et al.: Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016; 351(6271): 400-3
55. Iyombe-Engembe JP, Ouellet DL, Barbeau X, et al.: Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method. Mol Ther Nucleic Acids. 2016; 5: e283
56. Vulin A, Barthélémy I, Goyenvalle A, et al.: Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther. 2012; 20(11): 2120-33
57. Yokota T, Nakamura A, Nagata T, et al.: Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther. 2012; 22(5): 306-15
58. van Deutekom JC, Janson AA, Ginjaar IB, et al.: Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357(26): 2677-86
59. Lu Q, Cirak S, Partridge T: What Can We Learn From Clinical Trials of Exon Skipping for DMD? Mol Ther Nucleic Acids. 2014; 3(3): e152
60. http://www.ukmi.nhs.uk/applications/ndo/record_view_open. asp?newDrugID=4873. 2016
61. Kinali M, Arechavala-Gomeza V, Feng L, et al.: Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-ofconcept study. Lancet Neurol. 2009; 8(10): 918-28
62. Mendell JR, Rodino-Klapac LR, Sahenk Z, et al.: Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013; 74(5): 637-47
63. Mendell JR, Goemans N, Lowes LP, et al.: Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016; 79(2): 257-71
64. Hodgkinson L, Sorbera L, Graul AI: Duchenne muscular dystrophy drugs face tough path to approval. Drugs Today (Barc). 2016; 52(3): 199-202
65. Goyenvalle A, Griffith G, Babbs A, et al.: Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med. 2015; 21(3): 270-5
66. Gao X, Shen X, Dong X, et al.: Peptide Nucleic Acid Promotes Systemic Dystrophin Expression and Functional Rescue in Dystrophin-deficient mdx Mice. Mol Ther Nucleic Acids. 2015; 4(10): e255
67. Betts CA, Saleh AF, Carr CA, et al.: Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy. Sci Rep. 2015; 5: 11632
68. Lu-Nguyen NB, Jarmin SA, Saleh AF, et al.: Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice. Mol Ther. 2015; 23(8): 1341-8
69. Shabanpoor F, McClorey G, Saleh AF, et al.: Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy. Nucleic Acids Res. 2015; 43(1): 29-39
70. Meregalli M, Farini A, Sitzia C, et al.: Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect. Curr Gene Ther. 2015; 15(6): 563-71